Table 1.
Demographics and clinical characteristics of the participants.
| Characteristics | Pos (n=144) | Sus (n=100) | Ctr (n=40) | F-value | Pr (>F) | |
|---|---|---|---|---|---|---|
| Age | 8.472 | < 0.001 | ||||
| 1–20 years | 7 (4.9%) | 7 (7.0%) | 3 (7.5%) | |||
| 20–40 years | 45 (31.3%) | 57 (57.0%) | 14 (35.0%) | |||
| 40–60 years | 59 (40.9%) | 23 (23.0%) | 14 (35.0%) | |||
| >60 years | 33 (22.9%) | 13 (13.0%) | 9 (22.5%) | |||
| Gender | 0.602 | 0.548 | ||||
| Female (%) | 60 (41.7%) | 40 (40.0%) | 20 (50.0%) | |||
| Male (%) | 84 (58.3%) | 60 (60.0%) | 20 (50.0%) | |||
| Smoking history | ||||||
| Ongoing | 12 (8.3%) | 7 | NA | |||
| Never | 123 (85.4%) | 85 | NA | |||
| Ever | 9 (6.3%) | 8 | NA | |||
| Disease severity | ||||||
| Mild | 11 (7.6%) | NA | NA | |||
| Moderate | 102 (70.8%) | NA | NA | |||
| Severe | 13 (9.0%) | NA | NA | |||
| Critical | 18 (12.5%) | NA | NA | |||
| Length of stay | ||||||
| ≥14 days | 121 (84.0%) | NA | NA | |||
| ≥28 days | 47 (32.6%) | NA | NA | |||
| No relevant information | 8 (5.6%) | NA | NA | |||
| Symptoms | ||||||
| Cough | 93 (64.6%) | 86 (86%) | NA | |||
| Fever | 89 (61.8%) | 100 (100%) | NA | |||
| Sputum | 54 (37.5%) | 58 (58%) | NA | |||
| Fatigue | 27 (18.8%) | 20 (20%) | NA | |||
| Sore throat | 15 (10.4%) | 56 (56%) | NA | |||
| Muscle and joint pain | 15 (10.4%) | 34 (34%) | NA | |||
| Headache | 14 (9.7%) | 43 (43%) | NA | |||
| Gastrointestinal symptoms | 12 (8.3%) | 8 (8%) | NA | |||
| Dyspnea | 9 (6.3%) | 3 (3%) | NA | |||
| Runny nose | 8 (5.6%) | 24 (24%) | NA | |||
| Conjunctivitis | 2 (1.4%) | 0 | NA | |||
| Comorbidities | ||||||
| Yes | 79 (54.9%) | 56 (56%) | NA | |||
| No | 65 (45.1%) | 44 (44%) | NA | |||
| Antibiotics use | ||||||
| Yes | 65 (45.1%) | 16 (16%) | NA | |||
| No | 79 (54.9%) | 84 (84%) | NA | |||
| Clinical indicators value | ||||||
| Hb (g/L) | 146 (60–182) | NA | NA | |||
| PLT (×109/L) | 175 (63–368) | NA | NA | |||
| NEUT (%) | 66.1 (3.1–95.4) | NA | NA | |||
| LYMPH (%) | 24.2 (1.8–53.1) | NA | NA | |||
| MONO (%) | 6.2 (0.11–20.5) | NA | NA | |||
| EO (%) | 0.1 (0.0–3.8) | NA | NA | |||
| BASO (%) | 0.1 (0.0–1.3) | NA | NA | |||
| HCT (L/L) | 43.1 (0.2–51.5) | NA | NA | |||
| PCT (ng/ml) | 0.03 (0.01–109) | NA | NA | |||
| CRP (mg/L) | 8.75 (0.1–119.2) | NA | NA | |||
| ALT (IU/L) | 22.5 (3–151) | NA | NA | |||
| AST (IU/L) | 23 (9.8–502) | NA | NA | |||
| TBil (μmol/L) | 8.4 (2.0–45.9) | NA | NA | |||
| CREA (μmol/L) | 69 (14–969) | NA | NA | |||
| Outcome | ||||||
| Recovery | 82 (56.9%) | NA | NA | |||
| Improved | 24 (16.7%) | NA | NA | |||
| Continue to stay | 29 (20.1%) | NA | NA | |||
| Death | 1 (0.69%) | NA | NA | |||
| No relevant information | 8 (5.56%) | NA | NA | |||
NA, not available.